Drug Trial Radar · NCT01453205
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Last checked: Nov 20, 2026Latest source record: Mar 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
187
Actual
Start
Feb 27, 2012
Primary completion
Jul 11, 2016
Study completion Jul 11, 2016
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 17, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory DLBCL who are eligible for Autologous Stem Cell Transplant (ASCT), has superior efficacy compared to rituximab in the same population.
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
MEDI-551 2 mg/kgDrug
MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
RituximabDrug
Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
ICEDrug
ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
DHAPDrug
DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
Autologous Stem Cell Transplant (ASCT)Procedure
Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
MEDI-551 4 mg/kgDrug
MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Locations
81 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Burbank, California
Research Site
Palm Springs, California
Research Site
Sylmar, California
Research Site
Atlanta, Georgia
Research Site
Westwood, Kansas
Research Site
Hazard, Kentucky
Research Site
Lafayette, Louisiana
Research Site
Shreveport, Louisiana
Research Site
Baltimore, Maryland
Research Site
Minneapolis, Minnesota
Research Site
Rochester, Minnesota
Research Site
Kansas City, Missouri
Research Site
Kansas City, Missouri
Research Site
St Louis, Missouri
Research Site
The Bronx, New York
Research Site
Fargo, North Dakota
Research Site
Dayton, Ohio
Research Site
Newark, Ohio
Research Site
Sylvania, Ohio
Research Site
Hershey, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Charleston, South Carolina
Research Site
Knoxville, Tennessee
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Lubbock, Texas
Research Site
Morgantown, West Virginia
Research Site
Milwaukee, Wisconsin
Research Site
Saint John, New Brunswick, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Greenfield Park, Quebec, Canada
Research Site
Brno, Czechia
Research Site
Prague, Czechia
Research Site
Bordeaux, France
Research Site
Le Mans, France
Research Site
Libourne, France
Research Site
Marseille, France
Research Site
Marseille, France
Research Site
Pessac, France
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.